On July 8, Vale fell 3.06% in regular trading, trading at $14.21/share, with turnover of $131 million. The decline was triggered by Morgan Stanley downgrading the stock to Equal Weight from Overweight, while cutting its price target sharply to $16.50 from $19.50.

The downgrade follows a series of analyst reassessments this year. Barclays similarly downgraded Vale to Equalweight in April, citing narrowing valuation gaps with peers. RBC also trimmed its price target to $15 in June while maintaining a Sector Perform rating. The latest Morgan Stanley action further reduces consensus bullish conviction on the stock.

Adding to investor concerns, Vale's Board Chairman Daniel Stieler resigned on July 7 amid pressure from shareholder Previ, which had pushed for his removal. The company is also approaching key near-term catalysts, with sales data due July 21 and Q2 earnings scheduled for July 30, where analysts expect EPS of $0.51.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)